Editta Baldini - Concepedia

Author

Editta Baldini

Also Known As

C Boni, E BALDINI, E Baldini, E. BALDINI, E. Baldini, E.E. Baldini, Editta Baldini, GF Addamo, Oscar Alabiso, Otterson, Gregory A

136

Publications

3.7K

Citations

H-Index

Concepts

All Affiliations

Ospedale Santa Chiara University of Pisa Alleanza Contro il Cancro Istituto Tumori Bari Istituti di Ricovero e Cura a Carattere Scientifico

About

Editta Baldini is an author at Ospedale Santa Chiara specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	26	2.5K
2	Health Sciences	6	6	336
3	Cell Biology	2	2	81
4	Nursing	1	1	24
5	Public Health	1	1	84

Editta Baldini

Publications

3.3K

Citations

H-Index

Page 1

	Year	Citations
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial Naiyer A. Rizvi, Julien Mazières, David Planchard, The Lancet Oncology Checkmate 063Single-arm TrialMedicineImmunologyImmune Checkpoint Inhibitor	2015	1.4K
Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial Marcello Tiseo, Luca Boni, Francesca Ambrosio, Journal of Clinical Oncology Cancer ManagementPathologyArm BMaintenance SettingOncology	2017	182
Dose-Dense Adjuvant Chemotherapy in Early Breast Cancer Patients: Results From a Randomized Trial Marco Venturini, Lucia Del Mastro, Enrico Aitini, JNCI Journal of the National Cancer Institute	2005	149
Mutational Analysis in Cytological Specimens of Advanced Lung Adenocarcinoma: A Sensitive Method for Molecular Diagnosis Laura Boldrini, Silvia Gisfredi, Silvia Ursino, Journal of Thoracic Oncology Molecular DiagnosisMutational AnalysisCancer PathologySomatic VariantMedicine	2007	100
Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer. Pierfranco Conté, Editta Baldini, Alessandra Gennari, Journal of Clinical Oncology	1997	93
Platinum-Etoposide Chemotherapy in Elderly Patients With Small-Cell Lung Cancer: Results of a Randomized Multicenter Phase II Study Assessing Attenuated-Dose or Full-Dose With Lenograstim Prophylaxis—A Forza Operativa Nazionale Italiana Carcinoma Polmonare and Gruppo Studio Tumori Polmonari Veneto (FONICAP-GSTPV) Study Andrea Ardizzoni, Adolfo Favaretto, Luca Boni, Journal of Clinical Oncology	2005	88
Italian Nivolumab Expanded Access Program in Nonsquamous Non–Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients Marina Chiara Garassino, Alain Gelibter, Francesco Grossi, Journal of Thoracic Oncology Preclinical TherapeuticsTobacco ControlCancer ScreeningMedicineCancer Management	2018	84
Long-Term Results of Combined-Modality Therapy for Inflammatory Breast Carcinoma Editta Baldini, G. Gardin, Giuseppe Evangelista, Clinical Breast Cancer Breast OncologyMedicineBreast CancerCombined Modality TreatmentOncology	2004	75
Concomitant versus sequential administration of epirubicin and paclitaxel as first‐line therapy in metastatic breast carcinoma Pierfranco Conté, Valentina Guarneri, Paolo Bruzzi, Cancer	2004	69
Accelerated versus standard cyclophosphamide, epirubicin and5-fluorouracil or cyclophosphamide, methotrexate and5-fluorouracil: a randomized phase III trial in locally advanced breast cancer Editta Baldini, G. Gardin, Piergiorgio Giannessi, Annals of Oncology Advanced Breast CancerBreast OncologyMedicinePharmacologyBreast Cancer	2003	69

Page 1